Our cells have abilities that go far beyond the fastest, smartest computer. They generate mechanical forces to propel themselves around the body and sense their local surroundings through a myriad of channels, constantly recalibrating their actions.
The idea of using cells as medicine emerged with bone marrow transplants, and then CAR-T therapy for blood cancers. Now, scientists are beginning to engineer much more complex living therapeutics by tapping into the innate capabilities of living cells to treat a growing list of diseases.
Remove this text and use the embed button to add an image.
UCSF launched a Living Therapeutics Initiative to accelerate the development and delivery of revolutionary treatments.
That includes solid tumors like cancers of the brain, breast, lung, or prostate, and also inflammatory diseases like diabetes, Crohns, and multiple sclerosis. One day, this work may extend to regenerating tissues outside or even inside the body.
Taking a page from computer engineers, biologists are trying their hands at programming cells by building DNA circuits to guide their protein-making machinery and behavior.
We need cells with GPS that never make mistakes in where they need to go, and with sensors that give them real-time information before they deliver their payload, said Hana El-Samad, PhD, a professor of biochemistry and biophysics. Maybe they kill a little bit and then deliver a therapeutic payload that cleans up. And the next program over encourages the rejuvenation of healthy cells.
These engineered cell therapies would be a huge leap from traditional therapies, like small molecules and biologics, which can only be controlled through dose, or combination, or by knowing the time it takes for the body to get rid of it.
If you put in drugs, you can block things and push things one way or the other, but you can't read and monitor whats going on, said Wendell Lim, PhD, a professor of cellular and molecular pharmacology who directs the Cell Design Institute at UCSF. A living cell can get into the disease ecosystem and sense what's going on, and then actually try to restore that ecosystem.
Like people, cells live in communities and share duties. They even take on new identities when the need arises, operating through unseen forces that biologists term, self-organizing.
We need cells with GPS that never make mistakes in where they need to go, and with sensors that give them real-time information before they deliver their payload.
Hana El-Samad, PhD
Some living cell therapies could be controlled even after they enter the body.
Lim and others say it is possible to begin adapting cells into therapy, even when so much has yet to be learned about human biology, because cells already know so much.
Their built-in power includes dormant embryonic abilities, so a genetic nudge in the right place could enable a cell to assume a new function, even something it has never done before.
When a cell, a building block thats 10 microns in diameter can do that, and you have 10 trillion of them in your body, its a whole new ballgame, said Zev Gartner, PhD, a professor of pharmaceutical chemistry who studies how tissues form. Were not talking about engineering in the same way that somebody working at Ford or Intel or Apple or anywhere else thinks about engineering. Its a whole new way of thinking about engineering and construction.
For several years now, synthetic biologists have been building rudimentary feedback circuits in model organisms like yeast by inserting engineered DNA programs. Recently, Lim and El-Samad put these circuits into mice to see if they could tamp down the excess inflammation from traumatic brain injury.
They demonstrated that engineered T-cells could get into the sites of injury in the brain and perform an immune-modulating function. But its just a prototype of what synthetic circuits could do.
You can imagine all kinds of scenarios of therapies that dont cause any side effects, and do not have any collateral damage, said El-Samad.
UCSF researchers are building ever more complex circuits to move cells around the body and sense their surroundings. They hope to load them with DNA programs that trigger the cells protein-making machinery to do things like remove cancerous cells, then repair the damage caused by the tumors haphazard growth.
Or they could make cells that send signals to finetune the immune system when it overreacts to a threat or mistakenly attacks healthy cells. Or build new tissue and organs from our bodys own cells to repair damage associated with trauma, disease, or aging.
The fact that biological systems and cellular systems can self-organize is a huge part of biology, and thats something were starting to program, Lim said. Then we can make cells that do the functions that we want. We aspire to not only have immune cells be better at killing and detecting cancer but also to suppress the immune system for autoimmunity and inflammation or go to the brain to fight degeneration.
These UCSF scientists are on their way to engineering cell-based solutions to different diseases.
Tejal Desai, PhD, a professor and chair of the Department of Bioengineering and Therapeutic Sciences, is employing nanotechnology to create tiny depots where cells that have been engineered to treat Type 1 diabetes or cancer can refuel with oxygen and nutrients.
Having growth factors or other factors that keep them chugging along is very helpful, she said. Certain cytokines help specific immune cells proliferate in the body. We can design synthetic particles that present cytokines and have a signal that says, Come over to me. Basically, a homing signal.
Ophir Klein, MD, PhD, a professor of orofacial sciences and pediatrics, employs stem cell biology to research treatments for birth defects and conditions like inflammatory bowel disease. He is working with Lim and Gartner to create circuits that induce cells to grow in new ways, for example to repair the damage to intestines in Crohns disease.
Cells and tissues are able to do things that historically we thought they were incapable of doing, Klein said. We dont assume that the way things happen or dont happen is the best way that they can happen, and were trying to figure out if there are even better ways.
Faranak Fattahi, PhD, a Sandler Faculty Fellow, is developing cell replacement therapy for damaged or missing enteric neurons, which regulate the muscles that move food through the GI tract. She generated these gut neurons using iPS cell technology.
What we want to do in the lab is see if we can figure out how these nerves are misbehaving and reverse it before transplanting them inside the tissue, she said. Now, she is working with Lim to refine the cells, so they integrate into tissues more efficiently without being killed off by the immune system and work better in reversing the disease.
Matthias Hebrok, PhD, a professor in the Diabetes Center, has created pancreatic islets, a complex cellular ecosystem containing insulin-producing beta cells, glucagon-producing alpha cells and delta cells.
Now, he is working on how to make islet transplants that dont trigger the immune system, so diabetes patients can receive them without immune-suppressing drugs.
We might be able to generate stem-cell derived organs that the recipients immune system will either recognize as self or not react to in a way that would disrupt their function.
In health, the community of cells in these islets perform the everyday miracle of keeping your blood sugar on an even keel, regardless of what you ate or drank, or how little or how much you exercised or slept.
To me, at least, thats the most remarkable thing about our cells, Gartner said. All of this stuff just happens on its own.
Go here to see the original:
- Issue: Cell Stem Cell - August 2nd, 2021
- Stem Cell Therapy & Alternative Medicine in Mexico ... - August 2nd, 2021
- Fetal Stem Cell - an overview | ScienceDirect Topics - August 2nd, 2021
- Stem cell therapy - SlideShare - August 2nd, 2021
- Essent Biologics Launches Human Mesenchymal Stem Cells For ... - August 2nd, 2021
- From Cells to Organs: The Present and Future of Regenerative Medicine - DocWire News - August 2nd, 2021
- USC Stem Cell scientists explore the latent regenerative potential of the inner ear - USC News - August 2nd, 2021
- Refining epilepsy treatment with brain organoids and AI - Monash University - August 2nd, 2021
- Astellas and Minovia link up on mitochondrial cell therapy programs - The Pharma Letter - August 2nd, 2021
- Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily - July 31st, 2021
- Colin Jackson health: Im in constant pain Athlete to undergo stem cell therapy to help - Express - July 31st, 2021
- The Talking Man: New Advances In Regenerative Medicine - Forbes - July 31st, 2021
- Medipost's clinical trial approved to evaluate efficacy of knee osteoarthritis treatment - Aju Business Daily - July 31st, 2021
- A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with... - July 31st, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - July 31st, 2021
- Treatment Approaches for Patients With R/R DLBCL - Targeted Oncology - July 31st, 2021
- Global $57.4 Billion Cell And Gene Therapy Manufacturing Market to 2028 - Rising Pressure on Drug Developers/Manufacturers to Meet the Growing Market... - July 31st, 2021
- Acute Myeloid Leukemia Fungal Infections: Types and Treatment - Healthline - July 31st, 2021
- Overview of DLBCL - Targeted Oncology - July 31st, 2021
- Roundtable Discussion: Participants Evaluate the Use of Transplant and MRD in Newly Diagnosed Multiple Myeloma - Targeted Oncology - July 31st, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market: Allogeneic transplant is projected to continue to hold a dominant market share - BioSpace - July 27th, 2021
- Researchers develop a cell culture test to detect substances that harm the placenta and embryo - News-Medical.net - July 27th, 2021
- FDA Approves KEYTRUDA (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With... - July 27th, 2021
- Cryopreservation of Unrelated Donor SCTs Safe, Effective in Patients Who Underwent HSCT - Hematology Advisor - July 27th, 2021
- Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer - The Institute of Cancer Research, London - The... - July 25th, 2021
- Study proposes repurposed drug to treat COVID-19 - The Hindu - July 25th, 2021
- Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema - News-Medical.Net - July 25th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 23rd, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 23rd, 2021
- Regenerative Medicine provides new hope and healing - Summit Daily News - July 23rd, 2021
- Emphysema Reversed in Mice Given Injection of Healthy Pulmonary Endothelial Cells - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Nelson: Gimpy girls have different means of recovery - Watertown Public Opinion - July 23rd, 2021
- Gene Therapy Protects Optic Nerve Cells and Vision in Mice with Retinal Injury and Glaucoma - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Has COVID-19 Opened up the Route to Market for Cell and Gene Therapy? - Pharmaceutical Executive - July 23rd, 2021
- Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments - OncLive - July 23rd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 23rd, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 21st, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 21st, 2021
- Stem Cell Therapy Gets Fast Track Status for Parkinson Disease - Monthly Prescribing Reference - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Donating a chance at life: Kokomo teacher donates stem cells to 75-year-old woman through Be the Match - Kokomo Perspective - July 21st, 2021
- Young Patients With Multiple Myeloma May Benefit From Tandem Autologous Hematopoietic Stem Cell Transplantation - Hematology Advisor - July 21st, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 21st, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 21st, 2021
- YOUR HEALTH: Finding cures by tracking cells - WQAD.com - July 21st, 2021
- Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer - News-Medical.Net - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 17th, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 17th, 2021
- For Patients with HIV and Cancer, a Multidisciplinary Treatment Approach is Critical - Targeted Oncology - July 17th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 15th, 2021
- The Memphis Institute of Regenerative Medicine Rebrands To Reflect Statewide Reach - UTHSC News - July 15th, 2021
- Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma - OncLive - July 15th, 2021
- TiTAN-1 Trial of GEN-011 Initiates Treatment in Patients With Solid Tumors - Targeted Oncology - July 15th, 2021
- Saving a life, fixing the world - The Jewish Standard - July 15th, 2021
- Exosome spray may be better able to heal damaged hearts - New Atlas - July 15th, 2021
- Prime Medicine uncloaks with $315M to push 'search and replace' gene editing treatments - FierceBiotech - July 13th, 2021
- Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS - OncLive - July 13th, 2021
- U.S. Stem Cell, Inc The New Generation Company In The ... - July 11th, 2021
- Stem Cell Therapy - Stemedix | Regenerative Medicine Also ... - July 11th, 2021
- FIRM, CAS further cooperate to advance reproductive medicine research_china.org.cn - China.org.cn - July 11th, 2021
- England's drug price watchdog rejects Orchard's groundbreaking gene therapy after first round of talks - FiercePharma - July 11th, 2021
- ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma - Targeted Oncology - July 9th, 2021
- Gene therapy for sickle cell disease: progress and competition - BioPharma Dive - July 9th, 2021
- Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere... - July 9th, 2021
- Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma - OncLive - July 9th, 2021
- More than $25m awarded to Monash researchers for vital medical research - Monash University - July 9th, 2021
- Magnetically-guided delivery of therapeutic stem cells into the brain - Advanced Science News - July 7th, 2021
- Stem cell therapy could make significant impact as opioid alternative - The Pharma Letter - July 7th, 2021
- Institute for Stem Cell Biology and Regenerative Medicine ... - July 5th, 2021
- Home - World Stem Cell Summit - July 5th, 2021
- Stem Cell Therapy & Regenerative Medicine Clearwater, FL ... - July 5th, 2021
- Ethical Issues in Stem Cell Research - July 5th, 2021
- Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com - Business Wire - July 3rd, 2021
- Regenerative Therapy Makes Headway in HF ... in the Right Patients - MedPage Today - July 3rd, 2021
- A New Era For FDA Regulation Of Cell And Tissue Products - Law360 - July 3rd, 2021
- Multiple myeloma treatment: Newest options, drugs, and more - Medical News Today - July 3rd, 2021
- Anti-CD22 CAR-T cell therapy as a salvage treatment - OTT | OTT - Dove Medical Press - July 3rd, 2021
- Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma - AJMC.com Managed Markets Network - July 3rd, 2021
- The cell therapy manufacturing market is projected to reach USD 14.5 billion by 2030, growing at - GlobeNewswire - July 3rd, 2021
- Cellular Model of a Developing Mouse Is Built With Spatial Resolution - Technology Networks - July 3rd, 2021